The Effect of Two Regimens of Hormone Replacement Therapy on the Haemostatic Profile in Postmenopausal Women by Wersch, J. W. J. van et al.
Van Wersch et al.: Hormone replacement therapy and haemostatic profile 449
Eur. J. Clin. Chem. Clin. Biochem.
Vol. 32, 1994, pp. 449-453
© 1994 Walter de Gruyter & Co.
Berlin · New York
The Effect of Two Regimens of Hormone Replacement Therapy
on the Haemostatic Profile in Postmenopausal Women
By J. W. J. van Wersch \ J. M. H. Ubachs2, A. van den Ende3, and A. van Enk4
1
 Department of Haematology, De Wever Hospital, Heerlen, The Netherlands
2
 Department of Gynaecology, De Wever Hospital Heerlen, The Netherlands
3
 Department ofClinical Chemistry, Slotervaart Hospital, Amsterdam, The Netherlands
4
 Department of Gynaecology, Slotervaart Hospital, Amsterdam, The Netherlands
(Received January 17/March 9, 1994)
Summary: The effect of two different regimens of hormone replacement therapy on coagulation and fibrinolysis
was measured in 30 women taking Tibolone (Livial®) and 30 taking oestradiol valerate, sequentially combined with
cyproterone acetate (Climen®). Blood samples were taken before the beginning of the medication, then six and
twelve months afterwards. The Livial® group showed a rise of fibrinolytic activity äs measured by the a2-antiplas-
min-plasmin complexes. Tissue plasminogen activator antigen and plasminogen activator inhibitor-1 decreased
simultaneously. No effect was seen in the coagulation variables. In the Climen® group no significant alterations
were noticed, either in the coagulation or in the fibrinolysis variables. In the direct comparison of both substances
only factor VII appeared to be significantly higher in the Climen® group after six months and one year of treatinent.
Introduction
Hormonal replacement therapy has atträcted increasing
interest in recent decades. It is now used by a substantial
number of women to overcpme the various complaints
of the menopause. In cases of an intact uterus, prep-
arations are üsed in which the oestrogen component is
either sequentially or continuously combined with a pro-
gestagen to prevent pharmaceütically induced endo-
metrial hyperplasia and/or carcinöma (l, 2). Öestrogens
have a vasodilatatory effect and influence the serum
lipid coiicentrations favpuräbly (3—5). Because lipids
and haemostasis are linked (6—9), it is of interest to
study the haemostatic effects of hormonal replaeement
therapy. Öestrogens have been reported to enhance the
plasma concentrations of several coagulation factors (fi-
brinogen, FII, VII, VHI:c, IX, X and XII) and the fi-
brinolysis factor plasminogen (10—13), whereas
antithrombin III Was shown to be diminished (12, 14),
The progestagens administered in hormonal replacement
therapy are either nortestosterone or progesterone deri-
vates. The effect of progestagens on serum 'lipid concen-
trations caii be summarized äs an increase in total chol-
esterol and LDL-cholesterol, and a decrease in HDL-
cholesterol and triacylglycerols (15), whereas progester-
one derivatives appear to have no effect on these quantit-
ies. Effects on haemostasis are not well documented.
Both an increase and decrease of fibrinogen have been
described during the normal cycle (16, 17). In general,
however, a significant influence on the haemostatic sys-
tem is not to be expected.
In this study the effect of two different regimens on the
haemostatic profile was measured. Tibolone (Livial®),
a synthetic steroid with oestrogenic, progestogenic and
androgenic-anabolic properties, was given in a dose of
2.5 mg däily. This regimen was compared with the ad-
ministration of 2 mg oestradiol valerate, which is im-
mediately metabolized to the natural human oestrogen,
oestradiol, and combined in the last 10 days of the cycle
with l mg cyproterone acetate (Climen®).
Cyproterone acetate is a 17-hydroxyprogesterone de-
rivative with progestogenic and anti-androgenic proper-
ties. Long-term cyclic treatment with cyproterone ace-
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Tab. 1. Comparison of the median values (25th-75th percentiles) of various coagulation quantities
at different stages of the Livial® and the Climen® treatment
(A = at Start; B = after 6 months; C = after 12 months).
Fibrinogen (g/l)
•
Factor VII (%)
Thrombin-antithrombin III ( g/l)
Prothrombin fragment 1 + 2 (nmol/1)
A
B
C
A
B
C
A
B
C
A
B
C
Patients group
Livial®
median
(25th-75th
percentiles)
3.6
(3.3 - 4.2)
3.6
(3.3 - 3.9)
3.6
(3.4 - 4.5)
90
(79 -114)
85
(78 - 98)
84
(75 -111)
2.3
(2.0 - 3.2)
2.3
(2.0 - 2.7)
2.3
(1.9 - 3.3)
1.10
(0.84- 1.35)
1.09
(0.95- 1.28)
1.20
(0.96- 1.40)
Significance*
p-value
Clirnen® .· r
median
(25th-75th
percentiles)
3.7 n. s.
(3.5 - 4.0)
3.6 n. s.
(3.3 - 4.0)
3.6 n. s.
(3.2 - 4.0)
97 n. s.
(87 -109)
117 0.004
(93 -130)
113 n. s.
(83 -132)
2.1 n. s.
(1.7 - 3.2)
2.1 n. s.
(1.9 - 3.1)
2.0 n, s.
(1.7 - 2.2)
0.95 n. s.
(0.81- 1.53)
1.08 n. s.
(0.82- 1.37)
1.14 n. s.
(0.91- 1.40)
* Mann-Whitney-U test
täte given in the mentioned dose has no effect on the
lipid metabolism (18). Livial® is known to lower fi-
brinogen and factors VII and VIII (19, 20), and to in-
crease antithrombin III (21); enhanced fibrinolytic ac-
tivity has been reported (19, 20). In the present study
the haemostatic effects of Livial® and Climeri® were
compared. The essential difference between the two
preparations is the presence and absence, respectively,
of androgenic-anabolic properties.
Methods
Coagulation measurements
Fibrinogen was measured with a clotting assay (Merz and Dade)
according to the method of Clauss, by means of a Schnittger &
Gross coagulometer. F VII concentrations were assessed with an
amidolytic test kit of Kabi Vitrum Diagnostica (Mölndal, Sweden).
The prothrombin fragment l + 2 test was determined with an
ELISA test kit (Behring Corporation, Marburg, Germariy). For the
'thrombin-antithrombin determination an ELISA test kit
(Behring Corporation, Marburg, Germany) was used.
Fibrinolysis measurements
The D-dimer fibrin degradation products were measured by means
of the FbDP test (Organen Technika, Boxtel, The Netherlands). The
FbDP is a specific ELISA test fpr the determination of degradation
products of cross-lmked fibrin only, and not of fibrinogen. For tis-
sue plasminogen activator antigen and plasminogen activator in-
hibitor-1, ELISA test kits from Innogenetics (Antwe , Belgium)
were used. The a^-antiplasmin-plasmin complex determinations
were from Behring Corporation (Marburg, Germany).
Samples
Blood samples were drawn in citrate^containing plastic tubes after
fasting ovemight between 8.30 and 9.30 a. m. and a resting period
of 20 min before venipuncture. Alcohbl was not allowed the pre-
vious day. The analysis was conducted in citrated plasma prepared
by centrifugation of nine volumes freshly collected blood with one
volume trisodium citrate (0.11 mol/1) for 10 min (1600g) at 25 ?C.
The plasma was stored at -70 °C in plastic tubes and thawed with
tap water of 37 PC for 5 min before seriai analysis. .
Triäl design
Sixty healthy women with menopausal complaints, in the age
groüp of 45-55, and between l —5 years after the menopause were
admitted to an open randomized, comparative clinical trial over 12
treatment cycles. Their body weight was within Standard weight
± 10% (22). Women with a history of drugs, smoking more than
10 cigarettes per day and/or drinking more than 40 ml of alcohol
Oper day were excluded frorn the study. They took no preparations
which might influence lipids. Two menopausal centres participated
aiid each centre included 30 women. Randbmization was conducted
in blocks of 30. Each group used either Livial^ or Climen® con-
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tinuously for 12 monlhs. Livial® (Tiboione) was given in a dosage
of 2.5 mg daily, without a tablet-free interval. The Climen® regi-
men consisted of 21 tablets containing 2 mg of oestradiol valerate
with the last 10 tables containing additionally l mg cyproterone
acetate and a 7-day tablet-free interval between every cycle. Medi-
cation was taken at about the same time in the evening. Blood
samples were taken before the Start of the medication and between
cycle days 18-21 of treatment cycles 6 and 12.
Statistics
The significance of the differences was assessed by the Mann-Whit-
ney U test (level of significance p = 0.05).
The significance of the trends of the various analytes during the
two treatment options was computed by the Kruskal-Wallis test
(significance level p = 0.05).
Results
In table l the comparison of the median values (25—
75 percentiles) of the various coagulation quantities at
different stages of Livial® and Climen® treatment are
given. The only quantity showing a statistically signifi-
cant difference in concentration between the Livial® and
Climen^ groups six months after the Start was factor
VII, although there was still no significant trend after
one year of treatment. The results of the fibrinolysis
quantities show more significances when compared at
the different stages of treatment (tab. 2).
Tissue plasminogen activator concentrations were sig-
nificantly lower in the Livial® than in the Climen®
group both after six months and after one year of treat-
ment. Parallel behaviour was seen for plasminogen acti-
vator inhibitor-1 at the same stages of medication. The
Livial® group showed higher values for a2-antiplasmin-
plasmin complex after six and twelve months of treat-
ment. The various coagulation and fibrinolysis quantities
during Livial® and Climen® treatment were compared
(at Start, after 6 and 12 months), using the Kruskal-
Wallis test. In the coagulation series, no trend was found
in the course of one year of treatment with Climen®.
With Livial® there were significant decreasing trends for
tissue plasminogen activator (p = 0.01) and plas-
Tab. 2. Comparison of the median values (25th—75th percentiles) of various fibrinolysis quantities
at different stages of the Livial® and the Climen® treatment
(A = at start; B = after 6 months; c = after 12 months).
Tissue plasminogen activator ^g/l)
Plasminogen activator inhibitpr-1 (\ig/\)
D-dimer (μg/l)
a2-Antiplasmin-plasmin complex (\ig/\)
A
B
C
A
B
C
A
B
•
C
A
B
C
Patients group
Livial®
median
(25th-75th
percentiles)
4.5')
(3.1- 5.8)
3.01)
(2.3- 4.2)
3.5')
(1.9- 4.9)
682)
(46 - 91)
472)
(37 - 62)
392)
(29 - 64)
240
(200 -360)
240
(190 -350)
240
(185 -320)
2903)
(195 -400)
4253)
(365 -660)
4353)
(330 -650)
Climen®
median
(25th~75th
percentiles)
4.4
(3.7- 5.7)
4.7
(3.5- 5.8)
4.6
(3.5- 5.6)
70
(48 -106)
73
(41 -103)
62
(44 - 80)
250
(190 -360)
250
(190 -330)
233
(170 -340)
250
(183 -380)
260:
(200 -335)
238
(185 -335)
Significance*
p-value
n. s.
0.004
0.042
n. s.
0.02
0.02
n. s.
n. s.
n. s.
n. s.
<0.001
<0.001
* Mann-Whitney-U test
') Kruskal-Wallis test A/B/C, p = 0.01
2) Kruskal-Wallis test A/B/C, p = 0.005
3) Kruskal-Wallis test A/B/C, p = 0.005
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minogen activator inhibitor-1 (p = 0.005) and a signifi-
cant increase for a2-antiplasmin-plasmin complex
(p = 0.0005).
Discussion
Coagulation and fibrinolysis were studied during a one
year treatment of postmenopausal women with Livial®
or Climen®, to investigate the influence of this medi-
cation on the haemostatic profile, and to establish poten-
tial differences in coagulation and fibrinolysis at Start
and after six and twelve months of treatment. The two
substances differ considerably in their chemical compo-
sition and pharmacological mechanisms. As androgenic-
anabolic substances are known to influence the fi-
brinolytic System, it might be expected that the adminis-
tration of Livial®, which has an androgen-anabolic con>
ponent, would give rise to changes in the concentrations
of fibrinolysis markers (23—25). This is confirmed by
the changes in the fibrinolysis markers, tissue plasmin-
ogen activator, plasminogen activator inhibitor-1 and 012-
antiplasmin-plasmin complex and the consistency of the
coagulation quantities. During the Climeii® medication
no influence on the studied coagulation and fibrinolysis
markers was found. Evaluation of the results of both
regimens confirms therefore the indifferent behaviour of
Climen® in this respect. Livial® medication induced an
enhancement of a2-antiplasmin-plasmin complex, which
is indicative of an activation of the fibrinolysis System.
In general this effect might be considered to be advan-
tageous. It is in line with previous studies (19, 20) which
also reported a Stimulation of the fibrinolysis by Livial®,
although less sensitive methods were used (19, 20).
Earlier studies, indicating that Livial® lowers the level
of factor VII and of fibrinogen, were not confirmed. It
could only be demonstrated that at the two stages of
treatment the factor VII concentrations were lower in
the Livial® group thän in the Climen® group.
In conclusion, both medications are indifferent to the
coagulation System. Climen® is indifferent to the fi-
brinolysis System, whereas the Livial® regimen gave rise
to a stimulated fibrinolytic activity, of which the clinical
significance is still unclear.
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